Researchers have discovered that two mutations in the estrogen receptors in breast tumors are linked to the length of survival — even if the tumors have spread. Knowledge of such mutation can inform treatment decisions and benefit patients.
Two new studies published in The Lancet suggest that two different classes of drugs, aromatase inhibitors (AIs) and bisphosphonates, can reduce breast cancer deaths in postmenopausal women with early breast
A new study shows that a type of androgen-blocking drug, an aromatase inhibitor (marketed since 2005 to reduce the risk of breast cancer) is at least as effective against a common hormonal disorder as standard treatment.
Anastrozole, a drug that blocks estrogen production in postmenopausal women, has been shown to be effective in reducing a woman s risk of developing breast cancer, especially if she is at an elevated risk. This preventive approach may help to reduce mastectomies.